Core Viewpoint - The article highlights the strategic expansion of Microsoft in the healthcare and life sciences sector through the appointment of Larry Jones, who brings over 35 years of experience in medical technology and digital transformation from Johnson & Johnson MedTech [1][2][9]. Group 1: Larry Jones's Role and Responsibilities - Larry Jones will lead Microsoft's strategic development in healthcare and life sciences, focusing on the application of AI, cloud technology, and data analytics in the medical industry [2][9]. - His experience will be pivotal in driving innovation and deployment in digital healthcare solutions, personalized medicine, and telemedicine [2][9]. Group 2: Achievements at Johnson & Johnson - Jones led a $200 million global digital transformation plan at Johnson & Johnson, emphasizing cloud technology, IoT, and AI in medical devices [4][5]. - He was instrumental in advancing the VELYS orthopedic surgical robot platform and supporting the Ottava soft tissue surgical robot project, establishing a technological foundation in the soft tissue surgical robot field [5][6]. Group 3: Strategic Partnerships and Innovations - Jones facilitated a strategic partnership between Johnson & Johnson MedTech and Microsoft, selecting Microsoft Azure as the preferred cloud platform for digital surgical solutions, integrating AI, machine learning, and data analytics to enhance surgical precision and reduce intraoperative risks [5][6]. - His leadership in technology innovation has made him a recognized expert in digital transformation within the medical technology sector [5][6]. Group 4: Transition at Johnson & Johnson - Jones's departure from Johnson & Johnson marks a significant change, with Jeff Srour succeeding him as CIO, who will continue to drive digital healthcare and innovative technologies [7][8]. - Jones's retirement concludes a 35-year career at Johnson & Johnson, during which he held multiple key positions and contributed to significant technological advancements [6][7]. Group 5: Future Outlook for Microsoft - Jones's addition to Microsoft is expected to enhance the company's position in the global healthcare industry, leveraging his digital transformation experience to drive advancements in medical technology [9]. - The ongoing digital transformation at Microsoft is anticipated to accelerate the application of AI and cloud computing in healthcare solutions, improving accessibility and efficiency in global medical services [9].

? 公司拟变更 2024 年度利润分配预案，具体为：A 股每股派发现金红利由 ? 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。 ? 在实施权益分派的股权登记日前若公司总股本发生变动的，公司拟维持 分配总额不变，相应调整每股分配比例，并将另行公告具体调整情况。 ? 本次利润分配方案不触及《上海证券交易所股票上市规则（2024 年 4 月 修订）》 （以下简称《股票上市规则》）第 9.8.1 条第一款第（八）项规定的可能 被实施其他风险警示的情形。 证券代码：603122 证券简称：合富中国 公告编号：临 2025-022 合富（中国）医疗科技股份有限公司 关于变更 2024 年度利润分配预案的公告 本公司董事会及除独立董事 Stanley Yi Chang 先生以外的董事保证本公告 内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担法律责任。 重要内容提示： 一、2024 年度原利润分配预案内容 公司于 2025 年 3 月 11 日召开了第二届董事会第十四次会议、第二届监事会 第十四次次会议，审议通过了《关于公司 2024 ...

Meeting Overview - The second session of the Supervisory Board's sixteenth meeting was held on June 4, 2025, in Shanghai, with all three supervisors present, confirming the legality and validity of the meeting [1]. Resolutions Passed - The Supervisory Board unanimously approved the proposal to revise the "Director and Supervisor Remuneration Management System," which will be submitted to the shareholders' meeting for approval [2]. - The revised profit distribution plan for 2024 was deemed beneficial for the company's sustainable development and aligned with shareholder interests, ensuring no harm to minority shareholders [2][3].

证券代码：603122 证券简称：合富中国 公告编号：临 2025-023 合富（中国）医疗科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及及除独立董事Stanley Yi Chang先生以外的董事保证本公告 内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担法律责任。 重要内容提示： ? 股东大会召开日期：2025年6月25日 ? 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 一、 召开会议的基本情况 (一) 股东大会类型和届次 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 25 日 14 点 30 分 召开地点：上海市徐汇区虹漕路 456 号光启大楼 20 楼会议室 无。 二、 会议审议事项 本次股东大会审议议案及投票股东类型 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 25 日 至20 ...

独立董事候选人声明与承诺 本 人 翁文能，已充分了解并同意由提名人合富（中国） 医疗科技股份有限公司董事会提名为合富（中国）医疗科技 股份有限公司第三届董事会独立董事候选人。本人公开声明， 本人具备独立董事任职资格，保证不存在任何影响本人担任 合富（中国）医疗科技股份有限公司独立董事独立性的关系， 具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法 律、行政法规、部门规章及其他规范性文件，具有 5 年以上法 律、经济、会计、财务、管理或者其他履行独立董事职责所必需 的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培 训证明材料（如有） 二、本人任职资格符合下列法律、行政法规和部门规章 以及公司规章的要求： （一） 《中华人民共和国公司法》关于董事任职资格的规 定； （二）中国证监会《上市公司独立董事管理办法》、上海 证券交易所自律监管规则以及公司章程有关独立董事任职资 格和条件的相关规定； （三）其他法律法规、部门规章、规范性文件和上海证 券交易所规定的情形。 三、本人具备独立性，不属于下列情形： （四）在上市公司控股股东、实际控制人的附属企业任 职的人员及其配偶、父母、子女； ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-021 合富（中国）医疗科技股份有限公司 关于董事会换届选举的公告 本公司董事会及除独立董事 Stanley Yi Chang 先生以外的董事保证本公告 内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）第二届董事会于 （以下简称"《公司 法》"）、 《上海证券交易所股票上市规则》等法律、法规以及《合富（中国）医疗 科技股份有限公司章程》 为保证公司董事会的正常运作，在 2024 年年度股东大会审议通过前述事项 前，仍由第二届董事会按照《公司法》和《公司章程》等相关规定履行职责。 特此公告。 合富（中国）医疗科技股份有限公司董事会 附件：董事候选人简历 科学历。1983 年 11 月至 1996 年 4 月，任职于美国贝克曼仪器有限公司，担任 大中华区总经理；1996 年 5 月至 1996 年 9 月，任职于荷商飞利浦公司医疗部门， 担任大中华区总经理；1997 年 7 月至 2019 年 6 月担任合富生化科技股份有限公 司执行长；200 ...

Company Overview - Madi Technology closed at 15.44 yuan, up 2.93%, with a latest price-to-book ratio of 5.75 and a total market capitalization of 4.729 billion yuan [1] - As of the first quarter of 2025, there is one institutional holder of Madi Technology, holding a total of 49.2201 million shares valued at 0.637 billion yuan [1] Business Operations - Suzhou Madi Technology Co., Ltd. specializes in providing Clinical Information System (CIS) application software and overall solutions for clinical information management [1] - The company's main products include self-developed software, comprehensive solutions, purchased software and hardware, operational and technical services, medical service income, and photovoltaic battery cells [1] Financial Performance - For the first quarter of 2025, Madi Technology reported operating revenue of 63.34 million yuan, a year-on-year decrease of 43.13% [1] - The net profit for the same period was 23.5959 million yuan, showing a year-on-year increase of 138.55% [1] - The sales gross margin stood at 66.10% [1] Industry Comparison - Madi Technology's price-to-earnings (P/E) ratio (TTM) is -17.79, while the industry average is 113.36 [2] - The industry median P/E ratio is 20.17, indicating that Madi Technology's valuation is significantly lower than the industry average [2] - The total market capitalization of Madi Technology is 4.729 billion yuan, compared to the industry average of 11.359 billion yuan [2]

证券代码：688273 证券简称：麦澜德 公告编号：2025-019 南京麦澜德医疗科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 回购方案首次披露日 2024/7/2，由控股股东杨瑞嘉先生和史志怀先生提议 回购方案实施期限 2024 年 7 月 1 日~2025 年 6 月 30 日 预计回购金额 2,000万元~4,000万元 回购价格上限 31.61元/股 □减少注册资本 √用于员工持股计划或股权激励 回购用途 | □用于转换公司可转债 | | | --- | --- | | □为维护公司价值及股东权益 | | | 实际回购股数 | 108.21万股 | | 实际回购股数占总股本比例 | 1.08% | | 实际回购金额 | 2,135.1187万元 | | 实际回购价格区间 | 18.57元/股~26.00元/股 | | 一、回购审批情况和回购方案内容 | | 股股东杨瑞嘉先生和史志怀先生向公司董事会提议公司以自有资金通过集中竞价 交易方式实施股份回购。2024 年 7 月 1 日 ...

Group 1 - The core viewpoint of the news is that Yangpu Medical's stock has experienced a decline, with a closing price of 6.51 yuan, marking a 2.36% increase, but the latest price-to-book ratio is at a new low of 3.28 in 106 days, with a total market value of 2.013 billion yuan [1] - The company has seen a net outflow of main funds amounting to 4.2583 million yuan on June 3, and a total outflow of 9.6235 million yuan over the past five days, indicating a trend of capital withdrawal [1] - Yangpu Medical specializes in precision medicine, smart healthcare, and testing services, with its main product being a specimen management system [1] Group 2 - The latest financial performance report for the first quarter of 2025 shows that the company achieved an operating income of 116 million yuan, a year-on-year decrease of 18.15%, while net profit reached 7.8084 million yuan, reflecting a year-on-year increase of 344.71%, with a gross profit margin of 40.19% [1] - In comparison to industry averages, Yangpu Medical's price-to-earnings ratio (TTM) is -18.83, and its price-to-book ratio is 3.28, while the industry average P/E ratio is 50.80 [2] - The total market value of Yangpu Medical is reported at 2.013 billion yuan, which is significantly lower than the industry median of 5.019 billion yuan [2]

Group 1 - The development of AI in Shanghai is enhancing disease diagnosis and treatment, serving as a valuable assistant for clinicians and a tool for health education in schools, communities, and families [1][2] - The AI model "Qizhi," focused on children's brain health, has been launched in Shanghai, enabling rapid identification of brain abnormalities through patient-uploaded reports, thus improving diagnostic capabilities for grassroots doctors [1] - The "CardioMind" model, introduced at the 19th Oriental Cardiology Conference, showcases advanced multimodal data integration and deep reasoning capabilities, significantly improving diagnostic accuracy and reducing misdiagnosis [1] Group 2 - The establishment of the "Tumor-Cardiology AI Consortium" aims to address the challenges of treating immune myocarditis in cancer patients by integrating various myocardial injury markers and new indicators developed by a multidisciplinary team [2] - AI is expected to optimize medical resource allocation and enhance accessibility to healthcare services, extending its applications beyond hospitals to schools, communities, and homes [2] - The "Smart Eye Spirit," an AI eye health assistant, debuted during a children's eye health event, providing immediate answers to public inquiries about eye care [2] Group 3 - The accuracy and reliability of large models depend on the quality of training data, and challenges such as patient trust in digital doctors and compliance with ethical and regulatory standards must be addressed for AI's effective application in medicine [3]